Is Cosmos Health, Inc. overvalued or undervalued?

As of 18 May 2016, the valuation grade for Cosmos Health, Inc. moved from does not qualify to risky, indicating a deterioration in its financial standing. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of 0.54, an EV to EBIT of -1.87, and an EV to EBITDA of -2.06. In comparison, TFF Pharmaceuticals, Inc. has a less negative EV to EBITDA of 0.1173, suggesting that Cosmos is struggling relative to its peers.
The company's recent stock performance shows a 39.30% return year-to-date, significantly outperforming the S&P 500's 12.22% return in the same period. However, over longer horizons, such as the 3-year and 5-year returns of -89.93% and -98.82%, respectively, indicate severe underperformance compared to the S&P 500's gains. Overall, Cosmos Health, Inc. is deemed overvalued based on its financial metrics and peer comparisons.